
James Robert Brasic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4286215/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina (Lithuania), 2022, 58, 213.	2.0	9
2	Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study. Brain Sciences, 2022, 12, 314.	2.3	7
3	Classification of extremity movements by visual observation of signals and their transforms. MethodsX, 2022, 9, 101739.	1.6	3
4	Reply to Aljabali et al. Comment on "Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina 2022, 58, 213― Medicina (Lithuania), 2022, 58, 793.	2.0	0
5	The Effect of Vitamin D Supplementation on the Severity of Symptoms and the Quality of Life in Irritable Bowel Syndrome Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2022, 14, 2618.	4.1	11
6	An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. European Journal of Clinical Pharmacology, 2021, 77, 717-725.	1.9	10
7	The role of lumateperone in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532110340.	2.7	17
8	Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Idiopathic Autism Spectrum Disorder and Fragile X Syndrome: A Pilot Study. International Journal of Molecular Sciences, 2021, 22, 2863.	4.1	19
9	Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression. Neuropharmacology, 2021, 194, 108447.	4.1	10
10	Precision medicine to identify optimal diagnostic and therapeutic interventions for Parkinson's Disease. Medical Science and Discovery, 2021, 8, 514-519.	0.1	3
11	The Courage to Prevail. Oncologist, 2021, 26, 988-989.	3.7	0
12	MEASUREMENT OF CEREBRAL EXPRESSION OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 5 IN AUTISM SPECTRUM DISORDER AND FRAGILE X SYNDROME. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, S257.	0.5	1
13	Guidelines for the Diagnosis and Treatment of Parkinsonâ \in Ms Disease. , 2021, 9, .		1
14	An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy, 2020, 21, 139-145.	1.8	23
15	Dataset of quantitative structured office measurements of movements in the extremities. Data in Brief, 2020, 31, 105876.	1.0	5
16	Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome. Brain Sciences, 2020, 10, 899.	2.3	15
17	Beta-amyloid (Aβ) uptake by PET imaging in older HIV+ and HIV- individuals. Journal of NeuroVirology, 2020, 26, 382-390.	2.1	15
18	Differentiation of Zaghrouta, Ululation to Express Joy in the Middle East, from Movement Disorders and Other Conditions. International Journal of Health and Life Sciences. 2020, 7, .	0.5	2

#	Article	IF	CITATIONS
19	A cholecystokinin B receptor antagonist and cocaine interaction, phase I study. CNS Neuroscience and Therapeutics, 2019, 25, 136-146.	3.9	5
20	Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 235-241.	2.2	12
21	Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology, 2019, 44, 598-605.	5.4	207
22	A low-cost quantitative continuous measurement of movements in the extremities of people with Parkinson's disease. MethodsX, 2019, 6, 169-189.	1.6	20
23	Nuclear neurotransmitter molecular imaging of autism spectrum disorder. AIMS Molecular Science, 2019, 6, 87-106.	0.5	3
24	The Urgent Need for Molecular Imaging to Confirm Target Engagement for Clinical Trials of Fragile X Syndrome and Other Subtypes of Autism Spectrum Disorder. Archives of Neuroscience, 2019, 6, .	0.3	3
25	Metabotropic glutamate receptor 5 tracer [18F]-FPEB displays increased binding potential in postcentral gyrus and cerebellum of male individuals with autism: a pilot PET study. Cerebellum and Ataxias, 2018, 5, 3.	1.9	36
26	Characterization of 3 Novel Tau Radiopharmaceuticals, ¹¹ C-RO-963, ¹¹ C-RO-643, and ¹⁸ F-RO-948, in Healthy Controls and in Alzheimer Subjects. Journal of Nuclear Medicine, 2018, 59, 1869-1876.	5.0	81
27	Brain PET Imaging of α7-nAChR with [18F]ASEM: Reproducibility, Occupancy, Receptor Density, and Changes in Schizophrenia. International Journal of Neuropsychopharmacology, 2018, 21, 656-667.	2.1	47
28	Remission of Cilles de la Tourette Syndrome after Heat-Induced Dehydration. International Journal of Physical Medicine & Rehabilitation, 2018, 06, .	0.5	0
29	Are dopamine receptor and transporter changes in Rett syndrome reflected in Mecp2-deficient mice?. Experimental Neurology, 2018, 307, 74-81.	4.1	15
30	Linking dopaminergic reward signals to the development of attentional bias: A positron emission tomographic study. NeuroImage, 2017, 157, 27-33.	4.2	46
31	Molecular imaging of autism spectrum disorder. International Review of Psychiatry, 2017, 29, 530-554.	2.8	28
32	Learning Mechanisms Underlying Value-Driven Attention. Journal of Vision, 2017, 17, 1101.	0.3	0
33	The Role of Dopamine in Value-Based Attentional Orienting. Current Biology, 2016, 26, 550-555.	3.9	96
34	P4â€185: First inâ€human PET study of 3 novel tau radiopharmaceuticals: [¹¹ C]RO6924963, [¹¹ C]RO6931643, and [¹⁸ F]RO6958948. Alzheimer's and Dementia, 2015, 11, P850.	0.8	12
35	Quantitative Multi-modal Brain Autoradiography of Glutamatergic, Dopaminergic, Cannabinoid, and Nicotinic Receptors in Mutant Disrupted-In-Schizophrenia-1 (DISC1) Mice. Molecular Imaging and Biology, 2015, 17, 355-363.	2.6	13
36	GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding. Journal of the Neurological Sciences, 2015, 356, 118-123.	0.6	42

#	Article	IF	CITATIONS
37	Risky decision-making and ventral striatal dopamine responses to amphetamine: A positron emission tomography [11C]raclopride study in healthy adults. NeuroImage, 2015, 113, 26-36.	4.2	29
38	ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology, 2015, 232, 2863-2872.	3.1	28
39	Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use. CNS Drugs, 2015, 29, 313-330.	5.9	14
40	Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers. PLoS ONE, 2014, 9, e113694.	2.5	36
41	Brain PET Imaging in the Cannabinoid System. , 2014, , 27-36.		2
42	Radiotracers Used to Image the Brains of Patients with Alzheimerâ \in ™s Disease. , 2014, , 407-416.		5
43	Human Brain Imaging of Autism Spectrum Disorders. , 2014, , 373-406.		5
44	Human Brain Imaging of α7 nAChR with [18F]ASEM: a New PET Radiotracer for Neuropsychiatry and Determination of Drug Occupancy. Molecular Imaging and Biology, 2014, 16, 730-738.	2.6	69
45	History of childhood adversity is positively associated with ventral striatal dopamine responses to amphetamine. Psychopharmacology, 2014, 231, 2417-2433.	3.1	89
46	The Nicotine Hypothesis. , 2014, , 313-332.		3
46 47	The Nicotine Hypothesis. , 2014, , 313-332. Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence after a short-term abstinence. Psychiatry Research - Neuroimaging, 2014, 221, 92-96.	1.8	3 18
	Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence	1.8	
47	Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence after a short-term abstinence. Psychiatry Research - Neuroimaging, 2014, 221, 92-96. Objectively measured sleep and Î ² -amyloid burden in older adults: A pilot study. SAGE Open Medicine,		18
47 48	Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence after a short-term abstinence. Psychiatry Research - Neuroimaging, 2014, 221, 92-96. Objectively measured sleep and Î ² -amyloid burden in older adults: A pilot study. SAGE Open Medicine, 2014, 2, 205031211454652. Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography	1.8	18 41
47 48 49	 Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence after a short-term abstinence. Psychiatry Research - Neuroimaging, 2014, 221, 92-96. Objectively measured sleep and Î²-amyloid burden in older adults: A pilot study. SAGE Open Medicine, 2014, 2, 205031211454652. Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology, 2013, 229, 245-252. An In Vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients. 	1.8 3.1	18 41 26
47 48 49 50	 Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence after a short-term abstinence. Psychiatry Research - Neuroimaging, 2014, 221, 92-96. Objectively measured sleep and Î²-amyloid burden in older adults: A pilot study. SAGE Open Medicine, 2014, 2, 205031211454652. Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology, 2013, 229, 245-252. An In Vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients. Molecular Imaging and Biology, 2013, 15, 230-237. Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in 	1.8 3.1 2.6	18 41 26 36
47 48 49 50 51	Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence after a short-term abstinence. Psychiatry Research - Neuroimaging, 2014, 221, 92-96. Objectively measured sleep and β-amyloid burden in older adults: A pilot study. SAGE Open Medicine, 2014, 2, 205031211454652. Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology, 2013, 229, 245-252. An In Vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients. Molecular Imaging and Biology, 2013, 15, 230-237. Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. NeuroImage, 2013, 75, 282-290. ¹⁸ FrFPEB, a PET Radiopharmaceutical for Quantifying Metabotropic Glutamate 5 Receptors: A First-in-Human Study of Radiochemical Safety, Biokinetics, and Radiation Dosimetry. Journal of	1.8 3.1 2.6 4.2	18 41 26 36 26

JAMES ROBERT BRASIC

#	Article	IF	CITATIONS
55	Increased Synaptic Dopamine in the Putamen in Restless Legs Syndrome. Sleep, 2013, 36, 51-57.	1.1	93
56	Neurotransmitter visualization in schizophrenia. Journal of Biomedical Graphics and Computing, 2013, 3, .	0.2	2
57	Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone pain palliation treatment. Nuclear Medicine Communications, 2012, 33, 90-96.	1.1	17
58	Positron emission tomography experience with 2â€{ ¹⁸ F]fluoroâ€3â€{2(<i>s</i>)â€azetidinylmethoxy)pyridine (2â€{ ¹⁸ F]fa) in the livin human brain of smokers with paranoid schizophrenia. Synapse, 2012, 66, 352-368.	ng2	28
59	Correlation of the vesicular acetylcholine transporter densities in the striata to the clinical abilities of women with rett syndrome. Synapse, 2012, 66, 471-482.	1.2	19
60	Bone mineral density in postmenopausal Chinese women treated with calcium fortification in soymilk and cow's milk. Osteoporosis International, 2012, 23, 1563-1570.	3.1	41
61	The Dopamine Transporter is Decreased in the Striatum of Subjects with Restless Legs Syndrome. Sleep, 2011, 34, 341-347.	1.1	126
62	Differentiation of Non-Pharmacological from Pharmacological Dopamine Release in the Living Human Brain. Current Medical Imaging, 2011, 7, 104-106.	0.8	2
63	Alterations of Central Dopamine Receptors Before and After Gastric Bypass Surgery. Obesity Surgery, 2010, 20, 369-374.	2.1	189
64	Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. NeuroImage, 2010, 52, 1505-1513.	4.2	186
65	Inverted-U shape relation links impulsivity and dopamine receptor availability in ventral striatum. NeuroImage, 2010, 52, S109.	4.2	0
66	Parcellation of functional subdivisions of cingulate cortex and their agreements with distributions of multiple receptor systems. NeuroImage, 2010, 52, S194.	4.2	0
67	Multi-graphical analysis of dynamic PET. NeuroImage, 2010, 49, 2947-2957.	4.2	47
68	In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand ¹⁸ F-AV-45 (Flobetapir F 18). Journal of Nuclear Medicine, 2010, 51, 913-920.	5.0	607
69	Single photon emission computed tomography experience with (<i>S</i>)â€5â€{ ¹²³ 1]iodoâ€3â€{2â€ezetidinylmethoxy)pyridine in the living human brain of smoke and nonsmokers. Synapse, 2009, 63, 339-358.	er s 2	24
70	A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies. NeuroImage, 2009, 44, 661-670.	4.2	51
71	Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse, 2008, 62, 91-100.	1.2	180
72	VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. Journal of Neurochemistry, 2008, 105, 78-90.	3.9	111

JAMES ROBERT BRASIC

#	Article	IF	CITATIONS
73	Mechanisms of Dopaminergic and Serotonergic Neurotransmission in Tourette Syndrome: Clues from an In Vivo Neurochemistry Study with PET. Neuropsychopharmacology, 2008, 33, 1239-1251.	5.4	227
74	Monitoring People Treated with Isotretinoin for Depression. Psychological Reports, 2007, 100, 1312-1314.	1.7	8
75	Does Stimulant Medication Decrease the Lower Extremity Response Times of Children with and without Attention-Deficit/Hyperactivity Disorder?. Perceptual and Motor Skills, 2007, 104, 67-68.	1.3	1
76	Impulsivity and chronic stress are associated with amphetamine-induced striatal dopamine release. NeuroImage, 2007, 36, 153-166.	4.2	93
77	Brain imaging research: Does the science serve clinical practice?. International Review of Psychiatry, 2007, 19, 541-558.	2.8	33
78	A Qualitative and Quantitative Review of Obstetric Complications and Autistic Disorder. Journal of Developmental and Physical Disabilities, 2007, 19, 337-364.	1.6	9
79	An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. NeuroImage, 2006, 33, 550-563.	4.2	42
80	Sex Differences in Striatal Dopamine Release in Healthy Adults. Biological Psychiatry, 2006, 59, 966-974.	1.3	315
81	The Diagnosis of Esophageal Cancer by 2-deoxy-2-F-18 Fluoro-D-glucose Positron Emission Tomography (F-18 FDG PET). Clinical Nuclear Medicine, 2006, 31, 566-567.	1.3	2
82	Striatal Dopamine Release and Family History of Alcoholism. Alcoholism: Clinical and Experimental Research, 2006, 30, 1143-1151.	2.4	41
83	Reliable Classification of Case-Control Studies of Autistic Disorder and Obstetric Complications. Journal of Developmental and Physical Disabilities, 2006, 18, 355-381.	1.6	7
84	Dose effects of triazolam on brain activity during episodic memory encoding: a PET study. Psychopharmacology, 2006, 188, 445-461.	3.1	12
85	Screening People with Disturbed Sleep for Depression. Perceptual and Motor Skills, 2006, 103, 765-766.	1.3	2
86	Increased Occupancy of Dopamine Receptors in Human Striatum during Cue-Elicited Cocaine Craving. Neuropsychopharmacology, 2006, 31, 2716-2727.	5.4	280
87	Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboonPapio anubis. Synapse, 2005, 56, 94-99.	1.2	47
88	Relationships Among Ventral Striatal Dopamine Release, Cortisol Secretion, and Subjective Responses to Amphetamine. Neuropsychopharmacology, 2005, 30, 821-832.	5.4	295
89	Is stalking preventable?. Medical Hypotheses, 2005, 64, 878-879.	1.5	1
90	Suicide is probably more common in untreated youths than in those receiving treatment: The need for a retrospective epidemiological study. Medical Hypotheses, 2005, 65, 1204-1205.	1.5	2

#	Article	IF	CITATIONS
91	Characterization of dose dependent norepinephrine transporter blockade by atomoxetine in human brain using 11C MeNER PET. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S599-S599.	4.3	2
92	Spectral analysis with a minimal basis functions approach for quantification of ligand-receptor dynamic PET study. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S634-S634.	4.3	2
93	Neurobehavioral Assessment of Children and Adolescents Attending a Developmental Disabilities Clinic. Psychological Reports, 2004, 95, 1079-1086.	1.7	6
94	Documentation of Ethnicity. Psychological Reports, 2004, 95, 859-861.	1.7	5
95	Diagnosis of Benign Solitary Fibrous Tumors by Positron Emission Tomography. Southern Medical Journal, 2004, 97, 1264-1267.	0.7	11
96	NEUROBEHAVIORAL ASSESSMENT OF CHILDREN AND ADOLESCENTS ATTENDING A DEVELOPMENTAL DISABILITIES CLINIC. Psychological Reports, 2004, 95, 1079.	1.7	3
97	DOCUMENTATION OF ETHNICITY. Psychological Reports, 2004, 95, 859.	1.7	4
98	Assessing the Quality of the Administration of Psychoactive Medication. Journal of Developmental and Physical Disabilities, 2003, 15, 185-205.	1.6	4
99	Psychoactive Medication Quality Assurance Rating Survey (PQRS) Screening Criteria. Journal of Developmental and Physical Disabilities, 2003, 15, 231-254.	1.6	4
100	Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. NeuroImage, 2003, 18, 975-989.	4.2	117
101	Documentation of Demographic Data. Psychological Reports, 2003, 93, 151-152.	1.7	8
102	Obtaining Funding for New Researchers in Psychology. Psychological Reports, 2003, 93, 276-278.	1.7	0
103	Risks of the Consumption of Beverages Containing Quinine. Psychological Reports, 2003, 93, 1022-1024.	1.7	7
104	Differentiation of Zaghrouta, an Expression of Happiness by Women in the Middle East, from Medical Disease. Southern Medical Journal, 2003, 96, S35.	0.7	1
105	The Increased Likelihood of Obstetric Complications in Autistic Disorder. Southern Medical Journal, 2003, 96, S34.	0.7	3
106	DOCUMENTATION OF DEMOGRAPHIC DATA. Psychological Reports, 2003, 93, 151.	1.7	5
107	OBTAINING FUNDING FOR NEW RESEARCHERS IN PSYCHOLOGY Division of Nuclear Medicine Russell H. Morgan Department of Radiology and Radiological Science Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Psychiatry Bellevue Hospital Center and the New York University School of Medicine. Psychological Reports. 2003. 93. 276.	1.7	0
108	Positron emission tomography-a tool for identifying the effects of alcohol dependence on the brain. Alcohol Research, 2003, 27, 161-73.	1.0	14

JAMES ROBERT BRASIC

#	Article	IF	CITATIONS
109	Beneficial and Adverse Effects of Pets. Psychological Reports, 2002, 91, 444-444.	1.7	Ο
110	Elevated Intrasynaptic Dopamine Release in Tourette's Syndrome Measured by PET. American Journal of Psychiatry, 2002, 159, 1329-1336.	7.2	236
111	BENEFICIAL AND ADVERSE EFFECTS OF PETS. Psychological Reports, 2002, 91, 444.	1.7	Ο
112	Quinine-Induced Thrombocytopenia in a 64-Year-Old Man Who Consumed Tonic Water to Relieve Nocturnal Leg Cramps. Mayo Clinic Proceedings, 2001, 76, 863-864.	3.0	27
113	Do Families Comply with Child and Adolescent Psychopharmacology?. Child and Adolescent Psychopharmacology News, 2001, 6, 6-10.	0.1	1
114	Clinical Assessment of TICS. Psychological Reports, 2001, 89, 48-50.	1.7	8
115	In vivo imaging of neurotransmitter systems in neuropsychiatry. Clinical Neuroscience Research, 2001, 1, 35-45.	0.8	14
116	CLINICAL ASSESSMENT OF TICS. Psychological Reports, 2001, 89, 48.	1.7	3
117	Neuromotor Assessment and Autistic Disorder. Autism, 2000, 4, 287-298.	4.1	12
118	Differentiating Myoclonus from Tics. Psychological Reports, 2000, 86, 155-156.	1.7	9
119	Neurodevelopmental hypothesis of schizophrenia: a central sensory disturbance. Medical Hypotheses, 2000, 55, 314-318.	1.5	20
120	Progressive Catatonia. Psychological Reports, 1999, 84, 239-246.	1.7	17
121	CLINICIAN SAFETY. Psychiatric Clinics of North America, 1999, 22, 923-940.	1.3	18
122	Should People with Nocturnal Leg Cramps Drink Tonic Water and Bitter Lemon?. Psychological Reports, 1999, 84, 355-367.	1.7	18
123	Movements in autistic disorder. Medical Hypotheses, 1999, 53, 48-49.	1.5	18
124	A Review of the Literature and a Preliminary Study of Family Compliance in a Developmental Disabilities Clinic. Psychological Reports, 1998, 82, 275-286.	1.7	7
125	Clinical Assessment of Adventitious Movements. Psychological Reports, 1998, 83, 739-750.	1.7	7
126	Hallucinations. Perceptual and Motor Skills, 1998, 86, 851-877.	1.3	43

#	ARTICLE	IF	CITATIONS
127	Behavioral Effects of Clomipramine on Prepubertal Boys With Autistic Disorder and Severe Mental Retardation. CNS Spectrums, 1998, 3, 39-46.	1.2	16
128	PETS AND HEALTH. Psychological Reports, 1998, 83, 1011.	1.7	12
129	CLINICAL ASSESSMENT OF ADVENTITIOUS MOVEMENTS. Psychological Reports, 1998, 83, 739.	1.7	2
130	Clinical Assessment of Self-Injurious Behavior. Psychological Reports, 1997, 80, 155-160.	1.7	20
131	Hyperkinesias in a Prepubertal Boy with Autistic Disorder Treated with Haloperidol and Valproic Acid. Psychological Reports, 1997, 80, 163-170.	1.7	20
132	Dyskinesias Subside off All Medication in a Boy with Autistic Disorder and Severe Mental Retardation. Psychological Reports, 1997, 81, 755-767.	1.7	14
133	Unilateral auditory hallucinations in a boy with ipsilateral conductive hearing loss Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 302-302.	1.9	8
134	ADVERSE EFFECTS OF CLOMIPRAMINE. Journal of the American Academy of Child and Adolescent Psychiatry, 1997, 36, 1165-1166.	0.5	35
135	Psychoactive Medication Quality Assurance Rating Survey (PQRS). Journal of Developmental and Physical Disabilities, 1997, 9, 311-336.	1.6	12
136	Genetic Causes of Autism and the Pervasive Developmental Disorders. , 1990, , 183-216.		4
137	Neuroreceptor imaging of schizophrenia. , 0, , 78-87.		1